Clinical Study
Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa
Table 2
Results by Rituximab in OAL (review of the literature).
| | Patients | Diagnosis | Clinical stage | Rituximab dose | Outcome | Longer follows-up (months) |
|
Nückel et al. [36] | 2 | Relapsed after RT | IE | 375 mg/mq once weekly for 4 wks. | 1 CR 1 RP | 30 and 32 |
| Ferreri et al. [37] | 8 | 5 newly diagnosed 3 relapses | IE (4) IV (4) | 375 mg/mq once weekly for 4 wks. | 3 CR 2 PR 2 PD 1 SD | Not available |
| Tuncer et al. [39] | 10 | Newly diagnosed | IE | 375 mg/mq iv every 3 wks. for 6–8 cycles | 36% CR 64% PR | 31 |
| Zinzani et al. [40] | 1 | Newly diagnosed | IE | 375 mg/mq once weekly for 4 wks. | CR | — |
| Sullivan et al. [55] | 8 | Newly diagnosed | — | 375 mg/mq once weekly for 4 wks. | 5 CR, 2 PR 1 No Res | 32 |
| Heinz et al. [56] | 1 | Newly diagnosed | | 375 mg/mq once weekly for 4 wks. | CR | — |
| Mino et al. [57] | 10 | Newly diagnosed | I-IIE | 375 mg/mq every 4 wks. for 6–8 cycles | 10 CR | |
| Present study | 6 | Newly diagnosed | IE | 375 mg/mq every 3 wks. for 6 cycles + maintenance for 2 years | 4 CR 2 PR | 34 |
|
|